Additionally, savolitinib (Type I), a highly selective c-Met inhibitor, is currently in Phase III clinical trials for papillary renal cell carcinoma and other c-Met-driven malignancies [25]. This evidence concerns the gene MET and papillary renal cell carcinoma.